Ionis Pharmaceuticals, Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Ionis Pharmaceuticals, Inc. (IONS) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $81.88 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-24.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2021-02-24
- Ionis Pharmaceuticals, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2019 was $81.88M.
- Ionis Pharmaceuticals, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2016 was $43.34M.
- Ionis Pharmaceuticals, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2014 was $170.23M.
- Ionis Pharmaceuticals, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2012 was $57.56M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|
| 2019-12-31 | $81.88M 10-K · filed 2021-02-24 |
| 2016-12-31 | $43.34M 10-K · filed 2019-03-01 |
| 2014-12-31 | $170.23M 10-K · filed 2017-03-01 |
| 2012-12-31 | $57.56M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |